Recent developments in low molecular weight complement inhibitors
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
As a key part of the innate immune system, complement plays an important role not only in defending invading pathogens but also in many other biological processes. Inappropriate or excessive activation of complement has been linked to many autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer. A wide array of low molecular weight complement inhibitors has been developed to target various components of the complement cascade. Their efficacy has been demonstrated in numerous in vitro and in vivo experiments. Though none of these inhibitors has reached the market so far, some of them have entered clinical trials and displayed promising results. This review provides a brief overview of the currently developed low molecular weight complement inhibitors, including short peptides and synthetic small molecules, with an emphasis on those targeting components C1 and C3, and the anaphylatoxin receptors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rother, R. P., Rollins, S. A., Mojcik, C. F., Brodsky, R. A., & Bell, L. (2007) · Nature Biotechnology · doi:10.1038/nbt1344 · Cited by 778 · cited 1×
“Food and Drug Administration (FDA) recently approved human C1-Inh (Cinryze, ViroPharma) for hereditary angioedema (Cocchio and Marzella, 2009) and eculizumab (Soliris, Alexion Pharmaceuticals), a humanized anti-C5 monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria caused by an absence of the…”
Mario Governa, M. A. (2000) · Journal of Toxicology and Environmental Health, Part A · doi:10.1080/009841000156664 · Cited by 18
Cited by
Sarma, J. V., & Ward, P. A. (2011) · Cell and Tissue Research · doi:10.1007/s00441-010-1034-0 · Cited by 974
Zhu, L.-Y., Nie, L., Zhu, G., Xiang, L.-X., & Shao, J.-Z. (2013) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2012.04.001 · Cited by 548
Interactions between coagulation and complement—their role in inflammation
Oikonomopoulou, K., Ricklin, D., Ward, P. A., & Lambris, J. D. (2012) · Seminars in Immunopathology · doi:10.1007/s00281-011-0280-x · Cited by 486
Self-citationComplement control protein factor H: The good, the bad, and the inadequate
Ferreira, V. P., Pangburn, M. K., & Cortés, C. (2010) · Molecular Immunology · doi:10.1016/j.molimm.2010.05.007 · Cited by 420
Laskin, B. L., Goebel, J., Davies, S. M., & Jodele, S. (2011) · Blood · doi:10.1182/blood-2011-02-321315 · Cited by 315
Metadata
- Authors
- Qu, H., Ricklin, D., & Lambris, J. D.
- Venue
- Molecular Immunology
- Publisher
- Elsevier BV
- Published
- 2009-12
- Volume
- 47
- Issue
- 2-3
- Pages
- 185-195
- ISSN
- 0161-5890 (ISSN-L)
- OpenAlex
- W2154639063
- Cited by
- 109
- References
- 2
- FWCI
- 4.84
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recent developments in low molecular weight complement inhibitors. https://app.cochat.ai/papers/10.1016/j.molimm.2009.08.032
- The paper
- Qu, H., Ricklin, D., & Lambris, J. D. (2009). Recent developments in low molecular weight complement inhibitors. Molecular Immunology. https://doi.org/10.1016/j.molimm.2009.08.032
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.